What the FDA’s New GLP-1 Warning Means for Patients at Risk of Vision Loss
GLP-1 medications have become widely used to manage type 2 diabetes and support long-term weight management. Drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound have helped many patients manage chronic health conditions. However, a new safety announcement from the U.S. Food and Drug Administration (FDA) has raised concerns about a rare but potentially serious eye condition associated with this class of medications.
On November 9, 2026, the FDA announced that manufacturers of GLP-1 medications must add warnings about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). This condition affects the optic nerve and can cause sudden, painless vision loss in one eye. In some cases, the damage is permanent.
The announcement gives patients another reason to understand the potential risks of their medications, recognize concerning symptoms, and discuss questions with their healthcare providers. It also raises questions about whether drug manufacturers adequately communicated potential safety risks to patients.
What Is NAION and How Can It Affect Vision?
Non-arteritic anterior ischemic optic neuropathy, commonly called NAION, occurs when reduced blood flow damages the front portion of the optic nerve. The optic nerve carries visual information from the eye to the brain. When its blood supply becomes restricted, the resulting damage can interfere with a person’s ability to see.
NAION often develops suddenly and without pain. Some people first notice a change in vision when they wake up. Symptoms may include:
- Sudden blurred or reduced vision in one eye
- Blind spots or missing portions of the visual field
- Difficulty seeing clearly in the center of the visual field
- Changes in color perception
- Hazy or distorted vision
Vision loss from NAION can be permanent. The condition may also affect a person’s independence, ability to work, and capacity to perform everyday activities.
Patients should seek immediate medical attention if they experience sudden vision changes. Prompt evaluation by an eye specialist is important when NAION is suspected.
Which GLP-1 Medications Are Included in the FDA Warning?
The FDA’s November 2026 announcement applies to GLP-1 receptor agonist medications as a class. The agency identified NAION reports involving all currently marketed GLP-1 RA products and is requiring manufacturers to add information about the potential risk to the Warnings and Precautions sections of their medication labeling.
The affected medications include:
- Ozempic and Wegovy: Both contain semaglutide.
- Rybelsus: An oral form of semaglutide.
- Mounjaro and Zepbound: Both contain tirzepatide, which acts on both GIP and GLP-1 receptors.
- Victoza and Saxenda: Both contain liraglutide.
- Trulicity: Contains dulaglutide.
- Byetta and generic exenatide: Contain exenatide.
- Foundayo: Contains orforglipron.
Other combination products containing relevant GLP-1 activity are also included in the FDA’s labeling update.
Patients should not assume that a medication is exempt from the warning simply because it is prescribed for diabetes rather than weight management. The FDA’s update covers the medication class, not just drugs marketed for weight loss.
What Does the FDA’s Research Say About the Potential Risk?
The FDA reviewed clinical trial information, observational research, animal data, and reports of adverse events before announcing the new warning.
One part of the agency’s review examined 126 randomized clinical trials involving more than 134,000 participants. Researchers identified an incidence rate of approximately 6.4 NAION cases per 100,000 person-years among patients receiving GLP-1 medications, compared with 3.8 cases per 100,000 person-years among patients receiving placebo or other comparator medications.
The FDA also examined real-world patient data and published observational studies. Some findings suggested an increased risk compared with certain other diabetes medications, while other comparisons did not show a statistically significant difference.
These findings require careful interpretation. NAION remains rare, and the available research has not established that GLP-1 medications directly cause the condition. Patients may also have other risk factors that contribute to optic nerve damage.
However, the FDA determined that the available evidence justified additional safety information on medication labels. The announcement makes it important for patients and healthcare providers to discuss the potential risk when considering treatment.
Who May Have a Higher Risk of NAION?
NAION can affect people with different medical histories, but certain conditions may increase the likelihood of developing the condition. The FDA identifies several potential risk factors, including:
- Diabetes
- High blood pressure
- Smoking
- Sleep apnea
- Anemia
- Kidney disease
These factors are particularly important because many people prescribed GLP-1 medications already have underlying conditions that may affect their cardiovascular health or blood circulation.
A history of NAION also matters. Patients who have experienced the condition in one eye may face an increased risk of developing it in the other eye.
Anyone with concerns about their individual risk should discuss their medical history and treatment options with their healthcare team. Patients should not stop taking prescribed medication without first consulting their healthcare provider.
What Should Patients Do After Experiencing Vision Changes?
Patients taking GLP-1 medications should understand the symptoms of NAION and know when to seek medical attention. Sudden, painless vision loss in one eye, new blind spots, or other unexpected visual disturbances should never be ignored.
If these symptoms develop, patients should contact a healthcare professional immediately and seek prompt evaluation by an ophthalmologist. Delaying an assessment may make it more difficult to identify the cause and determine appropriate care.
Patients who receive a NAION diagnosis should also discuss their medication with their prescribing provider. The FDA advises healthcare professionals to consider discontinuing a GLP-1 medication in patients who develop NAION unless the benefits of continuing treatment clearly outweigh the risks.
Keeping medical records, prescription information, eye examination results, and treatment documentation can also help patients understand what happened and establish a timeline of their symptoms.
Could the New FDA Warning Lead to Product Liability Claims?
The FDA’s announcement raises important questions about pharmaceutical manufacturers’ responsibility to communicate potential medication risks. Drug companies must provide appropriate safety information so healthcare professionals and patients can make informed treatment decisions.
A product liability claim may arise when a medication allegedly causes serious harm because of a defect or inadequate safety warnings. In a failure-to-warn case, questions may include what the manufacturer knew about a potential risk, when that information became available, and whether the company provided appropriate warnings.
The new FDA announcement does not automatically establish that a manufacturer acted negligently or that every patient who developed NAION has a valid lawsuit. A potential claim requires an examination of the available medical and scientific evidence, the patient’s circumstances, and the manufacturer’s conduct.
Patients who experienced vision loss after using a GLP-1 medication may want to investigate whether the drug contributed to their injury and whether they have grounds to pursue compensation. Depending on the circumstances, a claim may involve medical expenses, lost income, ongoing treatment, and other damages recognized under New York law.
Alonso Krangle Fight for Victims After a Medication-Related Injury
A serious vision injury can change nearly every part of a person’s life. Patients who develop NAION may face permanent vision limitations, additional medical treatment, financial losses, and difficulty returning to their normal routines. The FDA’s November 2026 warning provides important new safety information for people taking GLP-1 medications. If you developed NAION or experienced significant vision loss after using one of these drugs, you may have questions about whether the medication contributed to your condition and whether the manufacturer provided adequate warnings. Alonso Krangle represents individuals pursuing compensation for injuries involving allegedly defective products and dangerous medications. Call us at 800-403-6191 or contact us online for a free consultation and confidential case evaluation.
Speak with An Attorney
Submit This Form or Call 800-403-6191